Eupraxia Pharmaceuticals Announces Positive Clinical Data from RESOLVE Trial of EP-104GI for Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company specializing in precision local drug delivery, recently released new data from its ongoing RESOLVE Phase 1b/2a trial investigating the effectiveness and safety of EP-104GI in treating eosinophilic esophagitis (EoE). EoE is a chronic inflammatory condition characterized by the presence of eosinophils, a type of white blood cell, in the esophagus. This condition leads to pain and difficulty swallowing food.
Improvements in Symptom Relief and Tissue Health
The latest data from the RESOLVE trial shows that histological scores and symptom scores continued to improve as the EP-104GI dose and area of esophageal coverage increased. Cohort 6, which received the highest dose and coverage, demonstrated the greatest symptom relief, as indicated by the lowest symptom distress index (SDI) scores, at the 12-week mark. Additionally, Cohort 6 showed the most significant improvements in tissue health, as measured by EoEHSS scores, and the greatest reduction in peak eosinophil counts (PEC) at 12 weeks.
Continuous Improvements and Dose-Response
Cohort 5 displayed the most significant symptom score reduction at 24 weeks, with continuous improvement in symptom relief over that time. For tissue health (EoEHSS) and PEC, there is a clear dose-response from Cohorts 3 to 6, with Cohort 6 exhibiting the greatest response.
Safety and Upcoming Webinar
The RESOLVE trial reported no serious adverse events or instances of oral or gastrointestinal candidiasis in any of the six cohorts. Eupraxia plans to host a webinar on Wednesday, February 26, 2025, at 11:00am PT to discuss the data from the RESOLVE trial in greater detail.
Personal Impact
For individuals diagnosed with eosinophilic esophagitis, these findings bring hope for an effective treatment that can help alleviate symptoms and improve tissue health. As more data becomes available, healthcare professionals may be able to offer personalized treatment plans based on the dose-response relationship and individual patient needs.
Global Significance
EoE affects millions of people worldwide, and the current standard of care relies on a strict diet, frequent esophageal dilation, and potent systemic steroids. The positive results from the RESOLVE trial may pave the way for a more targeted and effective treatment option for this chronic condition. By providing localized drug delivery, EP-104GI has the potential to improve the quality of life for those living with eosinophilic esophagitis and reduce the burden on healthcare systems.
Conclusion
Eupraxia Pharmaceuticals’ ongoing RESOLVE trial continues to yield promising results for EP-104GI as a potential treatment for eosinophilic esophagitis. With data showing continuous improvements in symptom relief and tissue health as the dose and coverage increase, Cohort 6 displayed the most significant improvements to date. The safety profile of EP-104GI, with no reported serious adverse events or oral/gastrointestinal candidiasis, adds to its potential as a viable treatment option. As the 12-week data from Cohort 7 is expected in Q2 2025, and the company plans to discuss the RESOLVE trial data further in an upcoming webinar, the future looks bright for those affected by eosinophilic esophagitis.
- Eupraxia Pharmaceuticals announces positive data from RESOLVE trial of EP-104GI for eosinophilic esophagitis
- Cohort 6 shows greatest symptom relief and tissue health improvements at 12 weeks
- No serious adverse events or oral/gastrointestinal candidiasis reported
- Webinar to discuss RESOLVE trial data on February 26, 2025
- EP-104GI has potential to provide targeted and effective treatment for eosinophilic esophagitis
